Daytime sleepiness associated with lurasidone and quetiapine XR: Results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 197-205

  Loebel, Antony D ^a   Siu, Cynthia O ^b   Cucchiaro, Josephine B ^a   Pikalov, Andrei A ^a   Harvey, Philip D ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b One Palomino Ct   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotics; daytime sleepiness; Epworth Sleepiness Scale; lurasidone; schizophrenia.

Indexed keywords

LURASIDONE; PLACEBO; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; AGITATION; ALERTNESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DSM-IV-TR; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SEDATION; TREATMENT OUTCOME; UNIVERSITY OF CALIFORNIA SAN DIEGO PERFORMANCE BASED SKILLS ASSESSMENT BRIEF VERSION SCORE; ACUTE DISEASE; AKATHISIA; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; COGNITIVE DEFECT; CONSTIPATION; DIZZINESS; DRUG DOSE INCREASE; FOOD INTAKE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE EXCITEMENT SUBSCALE; PSYCHOLOGICAL RATING SCALE; SCORING SYSTEM; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY OF CALIFORNIA SAN DIEGO PERFORMANCE BASED SKILLS ASSESSMENT BRIEF VERSION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901713564     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000904     Document Type: Review

References (30)

1. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008; 69(Suppl 1): 18-31.
2. Hawley CJ, Gale TM, Sivakumaran T, et al. Excessive daytime sleepiness in psychiatric disorders: prevalence, correlates and clinical significance. Psychiatry Res. 2010; 175(1-2): 138-141.
3. American Academy of Sleep Medicine (AASM). Driving Fact Sheet, December 2, 2009. http://www.aasmnet.org/Resources/ Factsheets/DrowsyDriving.pdf. Accessed July 26, 2012.
4. Colten HR, Altevogt BM, eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academy of Sciences. http://www.ncbi.nlm.nih.gov/ books/NBK19958. Accessed July 16, 2012.
5. Harvey PD, Hassman H, Mao L, et al. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar 1 disorder: A randomized, double-blind, crossover study. J Clin Psychiatry. 2007; 68(8): 1186-1194. (Pubitemid 47395620)
6. Johns MA. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991; 14(6): 540-545.
7. Johns MW. Epworth Sleepiness Scale (ESS). In Rush Jr AJ, First MB, Blacker D, Eds. Handbook of Psychiatric Measures, 2nd ed.Washington, DC: American Psychiatric Publishing; 2008.
8. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010; 13(8): 1115-1125.
9. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and activecontrolled trial. Schizophrenia Res. 2013; 145(1-3): 101-109.
10. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini- International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structural diagnostic psychiatric interview for DSM-IV and ICD-10 1996. J Clin Psychiatry. 1998; 59(Suppl 20): 22-23.
11. Baldwin CM, Scott LJ. Quetiapine extended release: In schizophrenia. CNS Drugs. 2009; 23(3): 261-269.
12. Zhornitsky S, Potkin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: A systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011; 26(4): 183-189.
13. Chervin RD. The multiple sleep latency test and Epworth Sleepiness Scale in the assessment of daytime sleepiness. J Sleep Res. 2000; 9(4): 397-400.
14. Lohr JB, Liu L, Caligiuri MP, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: A randomized, double-blind, placebocontrolled study. Schizophr Res. 2013; 150: 289-296.
15. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276. (Pubitemid 18039085)
16. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Res. 2004; 68(2-3): 331-337. (Pubitemid 38528742)
17. Pietrzak RH, Olver J, Norman T, et al. A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009; 31(7): 848-859.
18. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007; 33(6): 1364-1372. (Pubitemid 350022770)
19. Mackinnon DP, Fairchild AJ, Matthew SF. Mediation analysis. Annu Rev Psychol. 2007; 58: 593-614.
20. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002; 59(10): 877-883.
21. Harvey PD, Velligan DI. International assessment of functional skills in people with schizophrenia: Innovations in clinical neuroscience. Innov Clin Neurosci. 2011; 8(1): 15-18.
22. Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013; 23(11): 1373-1382.
23. Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediatereleased during 6-day initial dose escalation in bipolar depression: A multicenter, randomized, double-blind, phase IV study. Clin Ther. 2012; 34(11): 2202-2211.
24. Witek TJ Jr, Canestrari DA, Miller RD, et al. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol. 1995; 74(5): 419-426.
25. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171-181.
26. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-Analysis. Lancet. 2013; 382(9896): 951-962.
27. Horiguchi M, Huang M, Meltzer HY. The role of 5- hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011; 338(2): 605-614.
28. Guilleminault C, Brooks SN. Excessive daytime sleepiness: A challenge for the practising neurologist. Brain. 2001; 124(Pt 8): 1482-1491. (Pubitemid 32726763)
29. Rosenheck RA. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anti-cholinergics as a comparator. Psychiatr Serv. 2005; 56(1): 85-92. (Pubitemid 40094476)
30. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: A meta-Analysis. Lancet. 2009; 373(9657): 31-41.